5-(2,3-Dimethyl-3-tricyclo[2.2.1.02,6]heptanyl)-2-methylpent-2-enyl] acetate;[2-methyl-5-(2-methyl-3-methylidene-2-bicyclo[2.2.1]heptanyl)pent-2-enyl] acetate
Common Name: |
5-(2,3-Dimethyl-3-tricyclo[2.2.1.02,6]heptanyl)-2-methylpent-2-enyl] acetate;[2-methyl-5-(2-methyl-3-methylidene-2-bicyclo[2.2.1]heptanyl)pent-2-enyl] acetate |
IUPAC Name: |
[5-(2,3-dimethyl-3-tricyclo[2.2.1.02,6]heptanyl)-2-methylpent-2-enyl] acetate;[2-methyl-5-(2-methyl-3-methylidene-2-bicyclo[2.2.1]heptanyl)pent-2-enyl] acetate |
Molecular Formula: |
C12H20O |
SMILES: |
CC(=CCCC1(C2CCC(C2)C1=C)C)COC(=O)C.CC(=CCCC1(C2CC3C1(C3C2)C)C)COC(=O)C |
Inchi: |
1S/2C17H26O2/c1-11(10-19-12(2)18)6-5-7-16(3)13-8-14-15(9-13)17(14,16)4;1-12(11-19-14(3)18)6-5-9-17(4)13(2)15-7-8-16(17)10-15/h6,13-15H,5,7-10H2,1-4H3;6,15-16H,2,5,7-11H2,1,3-4H3 |
Inchi Key: |
ZUPBLUYKASBIGF-UHFFFAOYSA-N |
Cas No: |
1323-00-8 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
0 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
2 |
Name |
Value |
Molecular Weight (g/mol) |
180.29 |
Mass (g/mol) |
524.387 |
Molar Refractivity |
59.05 |
Net Charge |
|
HBD |
|
HBA |
1 |
Rt Bonds |
8 |
Rings |
2 |
TPSA |
17.07 |
Hetero Atoms |
2 |
Heavy Atoms |
13 |
Aromatic Heavy Atoms |
0 |
Melting Point (°C) |
|
Boiling Point (°C@760.00mm Hg) |
|
Vapor Pressure (mmHg@25.00 °C) |
|
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.58 |
LogP |
4.268 |
iLOGP |
3.06 |
XLOGP3 |
3.84 |
WLOGP |
3.66 |
MLOGP |
3.06 |
ESOL Log S |
-2.85 |
ESOL Solubility (mg/ml) |
0.255 |
ESOL Solubility (mol/l) |
0.001 |
ESOL Class: esol_class |
Soluble |
Ali Log S |
-3.89 |
Ali Solubility (mg/ml) |
0.02 |
Ali Solubility (mol/l) |
0 |
Ali Class |
Soluble |
Silicos-IT LogSw |
-2.82 |
Silicos-IT Solubility (mg/ml) |
0.27 |
Silicos-IT Solubility (mol/l) |
0 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
1 |
PgP Substrate |
0 |
Log Kp (cm/s) |
-4.67 |
Bioavailability Score |
0.55 |
Caco2 |
1 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
1.137 |
CYP1A2 Inhibitor |
1 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
0 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
2.456 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
0 |
Hepatotoxicity |
0 |
Androgen Receptor Binding |
1 |
Aromatase Binding |
1 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
1 |
Thyroid Receptor Binding |
1 |
BRCP inhibitor |
0 |
BSEP inhibitor |
1 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |